Piroxicam-d3 is intended for use as an internal standard for the quantification of piroxicam by GC- or LC-MS. Piroxicam is a COX inhibitor and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory and analgesic properties.1,2 It inhibits production of thromboxane B2 from arachidonic acid in HEL human erythroleukemic cells (IC50 = 0.45 ?M), which endogenously express COX-1, as well as inhibits LPS-induced formation of prostaglandin F1α from arachidonic acid in Mono-Mac-6 cells (IC50 = 0.77 ?M), which endogenously express COX-2.2 Lornoxicam reduces LPS-induced production of nitric oxide and IL-6 in cell-based assays with IC50 values of 240 and ~470 ?M, respectively. It reduces carrageenan-induced paw edema in rats when administered at doses of 1, 2.5, and 5 mg/kg.3 Formulations containing piroxicam have been used in the treatment of pain and inflammation associated with osteoarthritis and rheumatoid arthritis.
1.Pairet, M., van Ryn, J., Schierok, H., et al.Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4'-isomerInflamm. Res.47(6)270-276(1998) 2.Berg, J., Fellier, H., Christoph, T., et al.The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitroInflamm. Res.48(7)369-379(1999) 3.Buritova, J., Honore, P., Chapman, V., et al.Carrageenan oedema and spinal Fos-LI neurones are reduced by piroxicam in the ratNeuroreport6(10)1385-1388(1995)